Who are BNT162b5 Bivalent (WT/OMI BA.2)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Influenza, Comirnaty Original/Omicron BA.1, Tozinameran 6 months to 4 years of age, MVC-COV1901(3 Months), Tozinameran 12 Years of age and older, COVID-19 vaccination.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bnt162b5-bivalent-wt-omi-ba-2.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

BNT162b5 Bivalent (WT/OMI BA.2) — Competitive Intelligence Brief

BNT162b5 Bivalent (WT/OMI BA.2) (bnt162b5-bivalent-wt-omi-ba-2) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: mRNA vaccine. Area: Immunology.

marketed mRNA vaccine SARS-CoV-2 spike protein Immunology Live · refreshed every 30 min

Target snapshot

BNT162b5 Bivalent (WT/OMI BA.2) (bnt162b5-bivalent-wt-omi-ba-2) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
BNT162b5 Bivalent (WT/OMI BA.2) TARGET	bnt162b5-bivalent-wt-omi-ba-2	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein
Influenza	Influenza and COVID-19 Combination A	BioNTech	marketed	Non-Standardized Plant Allergenic Extract [EPC]	SARS-CoV-2 spike protein and influenza hemagglutinin protein
Comirnaty Original/Omicron BA.1	Comirnaty Original/Omicron BA.1	Jules Bordet Institute	marketed	mRNA vaccine	SARS-CoV-2 spike protein (original strain and Omicron BA.1 variant)
Tozinameran 6 months to 4 years of age	tozinameran-6-months-to-4-years-of-age	Pfizer	marketed	vaccine	SARS-CoV-2 spike protein
MVC-COV1901(3 Months)	MVC-COV1901(3 Months)	Taoyuan General Hospital	marketed	Protein subunit vaccine	SARS-CoV-2 spike protein
Tozinameran 12 Years of age and older	tozinameran-12-years-of-age-and-older	Pfizer	marketed	vaccine	SARS-CoV-2 spike protein
COVID-19 vaccination	COVID-19 vaccination	University Medical Center Groningen	marketed	vaccine	SARS-CoV-2 spike protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (mRNA vaccine class)

Pfizer · 12 drugs in this class
ModernaTX, Inc. · 11 drugs in this class
BioNTech SE · 5 drugs in this class
Jules Bordet Institute · 5 drugs in this class
Tan Tock Seng Hospital · 2 drugs in this class
Clover Biopharmaceuticals AUS Pty · 1 drug in this class
CanSino Biologics Inc. · 1 drug in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
CSPC Megalith Biopharmaceutical Co.,Ltd. · 1 drug in this class
Jens D Lundgren, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BNT162b5 Bivalent (WT/OMI BA.2) — Competitive Intelligence Brief. https://druglandscape.com/ci/bnt162b5-bivalent-wt-omi-ba-2. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab